Table 1.
Baseline characteristics of 85 patients with advanced hepatocellular carcinoma who received atezolizumab plus bevacizumab
| Characteristic | N = 85 |
|---|---|
| Sex, male, n (%) | 73 (85.9) |
| Age > 74, n (%) | 41 (48.2) |
| HBV positive, n (%) | 18 (21.2) |
| HCV positive, n (%) | 25 (29.4) |
| Child–Pugh class A, n (%) | 79 (92.9) |
| AFP > 400 ng/mL, n (%) | 32 (37.6) |
| BCLC stage C, n (%) | 52 (61.2) |
| Macrovascular invasion, n (%) | 18 (21.2) |
| Extrahepatic spread, n (%) | 35 (41.2) |
| Treatment line, atezolizumab plus bevacizumab,1st line, n (%) | 39 (45.9) |
| ECOG-PS ≤ 1, n (%) | 85 (100) |
| NLR ≥ 3.43, n (%) | 35 (41.2) |
Abbreviations: HBV hepatitis B virus, HCV hepatitis C virus, AFP alpha-fetoprotein, BCLC Barcelona Clinic Liver Cancer, ECOG-PS Eastern Cooperative Oncology Group Performance Status, NLR neutrophil-to-lymphocyte ratio